Authors
Miquel Martínez-Navarrete, Christian Sánchez-López, Antonio José Guillot García, M Carmen Recio, Rosa M Giner, Antonio Marcilla, Ana Melero
Published in
Journal of extracellular vesicles. Volume 15. Issue 11.
Abstract
Extracellular vesicles are gaining attention in the pharmaceutical field due to their potential as therapeutic and delivery platforms. Among these, plant nanovesicles (PNVs) are particularly promising due to their reported biological activity. Pomegranate (Punica granatum) has been widely used in traditional medicine for its antioxidant and anti-inflammatory properties. Recent studies have revealed that pomegranate juice contains PNVs with therapeutic potential. In this study, pomegranate-derived nanovesicles (PgNVs) were isolated, characterized, and pharmacologically evaluated in dermatitis-like in vivo murine models of delayed-type hypersensitivity (DTH) and chronic dermatitis. Subcutaneous administration of PgNVs modulated pro-inflammatory cytokine expression, particularly by reducing IL-4 and IL-1β levels in the DTH model. Moreover, in the chronic dermatitis model, PgNVs-treated mice exhibited reduced histopathological skin damage, decreasing epidermal hyperplasia, collagen deposition, and immune cell infiltration. Additionally, PgNVs enhanced the secretion of the anti-inflammatory cytokine IL-10, while decreasing the levels of pro-inflammatory mediators like IL-1β. Importantly, the long-term effects of PgNVs treatment were compared to those of topical corticosteroids (TCS), which constitute the current standard treatment for dermatitis. Unlike TCS, PgNVs did not induce side effects. Overall, these findings support the therapeutic potential of PgNVs as a promising, safe and sustainable alternative approach to treat chronic inflammatory skin diseases.
PMID:
42988731
Bibliographic data and abstract were imported from PubMed on 06 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 18
- Comments 0